Medical societies' recommendations for immunization with Human Papillomavirus vaccine and disclosure of conflicts of interests

Preventive Medicine

Volumn 48, Issue 5, 2009, Pages 449-453

  Marquez Calderon, Soledad ^a   Lopez Valcarcel, Beatriz G ^b   Segura, Andreu ^c  

^a Fundación Instituto de Investigación en Servicios de Salud   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^c INSTITUT CATALÀ DE LA SALUT   (Spain)

Author keywords

Conflict of interest; Guidelines; Medical societies; Papillomavirus vaccines

Indexed keywords

WART VIRUS VACCINE;

ARGENTINA; CANADA; CANCER PREVENTION; CHILE; CONFLICT OF INTEREST; DOCUMENT EXAMINATION; DRUG EFFICACY; DRUG INDUSTRY; FRANCE; HEALTH CARE SYSTEM; HUMAN; INTERNET; INTERPERSONAL COMMUNICATION; MEDICAL DOCUMENTATION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SPAIN; UNITED STATES; UTERINE CERVIX CANCER; WART VIRUS;

ALPHAPAPILLOMAVIRUS; CONFLICT OF INTEREST; DISCLOSURE; FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES; SOCIETIES, MEDICAL; UTERINE CERVICAL NEOPLASMS;

EID: 65549131191     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2009.02.018     Document Type: Review

References (23)

1. American Academy of Family Physicians, 2007. AAFP Policy Statement regarding consideration of the mandated use of HPV for school attendance. Available from: http://www.aafp.org/online/en/home/clinical/immunizationres/mandatedhpv.html (Acceded Nov. 2008).
2. American Board of Internal Medicine Foundation, American College of Physicians-American Society of Internal Medicine Foundation, European Federation ofInternal Medicine, 2002. Medical professionalism in the new millennium: a physician charter. Ann. Intern. Med. 136, 243-246.
3. Bekelman J.E., Li Y., and Gross C.P. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. J. Am. Med. Assoc. 289 (2003) 454-463
4. Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine 22 (2004) 3312-3322
5. Beutels P., Thiry N., and Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review [2002-2006]. Vaccine 25 (2007) 1355-1367
6. Blumenthal D. Doctors and drug companies. N. Engl. J. Med. 351 (2004) 1885-1890
7. Brennan T.A., Rothman D.J., Blank L., Blumenthal D., Chimonas S.C., Cohen J.J., et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. J. Am. Med. Assoc. 295 (2006) 429-433
8. Choudhry N.K., Stelfox H.T., and Detsky A.S. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. J. Am. Med. Assoc. 287 (2002) 612-617
9. Cohen J.J., Cruess S., and Davidson C. Alliance between society and medicine: the public's stake in medical professionalism. J. Am. Med. Assoc. 298 (2007) 670-673
10. De Kok I.M., Habbema J.D., Mourits M.J., Coebergh J.W., and Van Leeuwen F.E. Insufficient basis for the inclusion of human papillomavirus vaccination in the National Immunisation Programme in The Netherlands. Ned. Tijdschr. Geneeskd. 152 (2008) 2001-2004
11. Haug C.J. Human papillomavirus vaccination-reasons for caution. N. Engl. J. Med. 359 (2008) 861-862
12. King L.A., Levy-Bruhl D., O ' Flanagan D., Bacci S., Lopalco P.L., Kudjawu Y., et al. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: results of the VENICE 2007 survey. Euro Surveill. 13 (2008) 1-6
13. Kirch D.G. Conflict-of-interest management: efforts and insights from the Association of American Medical Colleges. Cleve. Clin. J. Med. 74 Suppl. 2 (2007) S23-25 discussion S32-37
14. Koulova A., Tsui J., Irwin K., Van Damme P., Biellik P., and Aguado M.T. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008. Vaccine 26 (2008) 6529-6541
15. Lee K. Has the hunt for conflicts of interest gone too far? No. BMJ 336 (2008) 477
16. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., and Unger E.R. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 56 RR-2 (2007) 1-24
17. Marquez-Calderon S. Negative effects of individual-based preventive interventions. 2008 SESPAS Report. Gac. Sanit. 22 Suppl. 1 (2008) 205-215
18. Martinez-Gonzalez M.A., Carlos S., and De Irala J. Human papillomavirus vaccine: optimism versus prudence. Med. Clin. (Barc) 131 (2008) 256-263
19. Ministerio de Salud del Gobierno de Chile, Pontificia Universidad Católica de Chile, 2008. Propuesta técnica. Estudio costo efectividad de la vacuna contra el papiloma virus humano. Available from: http://contacto.med.puc.cl/interconsulta/intercon_oct_08/PROPUESTA_TECNICA.doc (Acceded Nov. 2008).
20. Porta M., González B., Márquez S., and Artazcoz L. Doubts on the appropriateness of universal human papillomavirus vaccination: is evidence on public health benefits already available?. J. Epidemiol. Community Health 62 (2008) 667
21. Roughead E.E., Gilbert A.L., and Vitry A.I. The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy. Health Policy 88 (2008) 250-257
22. Sheldon T. Drug company campaign adds to pressure on Dutch doctors to vaccinate against HPV. BMJ 334 (2007) 819
23. The PLoS Medicine Editors. Making sense of non-financial competing interests. PLoS Med. 5 (2008) 199 10.1371/journal.pmed.0050199